Clinical Trial Update: An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 [Phase 3]

View source ↗

Summary

Extension study update for teduglutide in Japanese participants with Short Bowel Syndrome after 24 weeks of prior treatment in related trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Short Bowel Syndrome

Drugs mentioned

• Teduglutide (teduglutide)

Snippet

Sponsor: Takeda | Conditions: Short Bowel Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2023-03-15